This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
BMC Medical Genetics Open Access 17 January 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144–1145.
Baxter EJ, Scott LM, Campbell PJ, East C, Fouorouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 779–790.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.
Verstovsek S, Silver RT, Cross NCP, Tefferi A . JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, or less? Leukemia 2006; 20: 2067.
Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndrome (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 2005; 19: 2359–2360.
James C, Delhommeau F, Marzac C, Teyassandier I, Le Couédic J-P, Giraudir S et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350–353.
Scott LM, Scott MA, Campbell PJ, Green AR . Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108: 2435–2437.
Acknowledgements
We thank Professor J Patrick Barron for review of the manuscript and Mr Kunio Hori and Tohru Makino, NovusGene, Tokyo, for technical assistance. This work was supported in part by the ‘High-Tech Research Center’ Project from the Ministry of Education, Culture, Sports and Technology (MEXT) (to KO and JHO) and by the ‘University-Industry Joint Research Project’ from MEXT (to KO and JHO).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Ohyashiki, K., Aota, Y., Akahane, D. et al. JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 21, 1097–1099 (2007). https://doi.org/10.1038/sj.leu.2404604
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404604
This article is cited by
-
The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
BMC Medical Genetics (2012)
-
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation
International Journal of Hematology (2009)
-
Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia
International Journal of Hematology (2009)
-
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Leukemia (2008)
-
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
Leukemia (2008)